ArticleThe international journal of cardiovascular imaging2025
Right ventricular strain enhances the REVEAL LITE score for predicting 1-Year mortality in pulmonary hypertension.
Article in The international journal of cardiovascular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRight ventricular (RV) systolic dysfunction is crucial to the prognosis of pulmonary hypertension (PH). The value of incorporating right ventricular longitudinal strain (RVLS), a sensitive parameter for evaluating RV systolic function, in risk assessment tools has not been thoroughly investigated.
methodsThis study included adult patients with PH Group I or IV who had a transthoracic echocardiogram (TTE) within a year before starting PH-specific treatment. RV strain measurements were obtained by certified sonographers using strain software (Epsilon Imaging, Ann Arbor, MI). Variables for the REVEAL LITE 2.0 risk score were extracted from electronic medical records closest to the TTE date. A modified REVEAL LITE 2.0 score was created by subtracting or adding one point based on an ROC-derived cutoff for RVLS. ROC analysis was used to assess the area under the curve (AUC) for predicting all-cause mortality at one-year.
resultsA total of 161 patients were included. RVLS ≤ -14% was associated with lower risk of all-cause mortality at one-year compared to RVLS >-14% after adjustment for REVEAL LITE 2.0 (aHR: 0.19; 95% CI: [0.03 to 0.94]; p = 0.042). There was a significant difference in AUC between the REVEAL LITE 2.0 and modified REVEAL LITE 2.0 in predicting all-cause mortality at one-year (0.856 vs. 0.808, p = 0.037).
conclusionsRVLS was an independent predictor of all-cause mortality at one year in patients with PH. Incorporating RVLS into the REVEAL Lite 2.0 risk score may enhance its ability to predict all-cause mortality at one-year.
Indexed as
Identifiers
40884696What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.